Binding and Presentation of Lipid Antigens by CD1

CD1 与脂质抗原的结合和呈递

基本信息

  • 批准号:
    7251478
  • 负责人:
  • 金额:
    $ 33.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1999
  • 资助国家:
    美国
  • 起止时间:
    1999-07-01 至 2009-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The CD1 system of MHC class I-like proteins is firmly established as a group of antigen presenting molecules that activates T cells specific for lipids and glycolipids. A population of T lymphocytes known as NK T cells recognizes specific lipid ligands presented by the CD1d protein, and this component of the CD1-dependent immune response is highly conserved between humans and mice. Many detailed studies in mouse models have shown that CD1d-restricted NK T cells contribute to immune responses against pathogens, the elimination of malignant tumors, and the prevention of autoimmune diseases. A synthetic alpha-galactosyl ceramide known as KRN7000 has been identified as a glycolipid ligand that binds to CD1d and strongly activates multiple effector functions of NK T cells. Through collaborative efforts with established experts in the area of synthetic organic chemistry, the applicant has developed novel approaches to the creation of alpha-galactosyl ceramides with a range of structural alterations. Many of these compounds preserve the ability to activate CD1d-restricted NK T cells, and preliminary studies indicate that the have immunomodulatory activities that are significantly different from those of KRN7000. The current proposal will investigate the immunomodulatory activities of a large panel of novel alpha-galactosyl ceramides. Properties of these compounds to be investigated include induction of Th1 (inflammatory) versus Th2 (anti-inflammatory) cytokine production, specific targeting of NK T cell activation by certain types of antigen presenting cells or in certain tissues, and their ability to cause expansion as opposed to apoptosis of NK T cells. The proposed experiments will include in vitro cell culture studies of both human and murine NK T cells, and in vivo studies using mice. There is a high expectation that the proposed studies will contribute directly to the development of clinically useful immunomodulatory agents that act on NK T cells.
描述(由申请人提供):MHC I类蛋白的CD 1系统被牢固地建立为一组抗原递呈分子,可激活对脂质和糖脂特异性的T细胞。被称为NK T细胞的T淋巴细胞群体识别由CD 1d蛋白呈递的特异性脂质配体,并且CD 1依赖性免疫应答的这一组分在人类和小鼠之间高度保守。在小鼠模型中的许多详细研究表明,CD 1d限制性NK T细胞有助于对病原体的免疫应答,消除恶性肿瘤和预防自身免疫性疾病。被称为KRN 7000的合成α-半乳糖基神经酰胺已被鉴定为糖脂配体,其结合CD 1d并强烈激活NK T细胞的多种效应子功能。通过与合成有机化学领域的知名专家的合作努力,申请人已经开发了新颖的方法来创建 具有一系列结构改变的α-半乳糖基神经酰胺。这些化合物中的许多保留了激活CD 1d限制性NK T细胞的能力,初步研究表明,它们具有与KRN 7000显著不同的免疫调节活性。目前的建议将调查一个大面板的新型α-半乳糖神经酰胺的免疫调节活性。待研究的这些化合物的性质包括诱导Th 1(炎性)相对于Th 2(抗炎)细胞因子产生,通过某些类型的抗原呈递细胞或在某些组织中特异性靶向NK T细胞活化,以及它们引起与NK T细胞凋亡相对的扩增的能力。拟议的实验将包括人和鼠NK T细胞的体外细胞培养研究,以及使用小鼠的体内研究。人们高度期望所提出的研究将直接有助于开发作用于NK T细胞的临床有用的免疫调节剂。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Steven A Porcelli其他文献

Steven A Porcelli的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Steven A Porcelli', 18)}}的其他基金

Flow Cytometery and Cell Sorting Core
流式细胞仪和细胞分选核心
  • 批准号:
    10659181
  • 财政年份:
    2022
  • 资助金额:
    $ 33.5万
  • 项目类别:
Flow Cytometery and Cell Sorting Core
流式细胞仪和细胞分选核心
  • 批准号:
    10408970
  • 财政年份:
    2022
  • 资助金额:
    $ 33.5万
  • 项目类别:
Bigfoot Multispectral High Speed Fluorescence Activated Cell Sorter
Bigfoot 多光谱高速荧光激活细胞分选仪
  • 批准号:
    10414835
  • 财政年份:
    2022
  • 资助金额:
    $ 33.5万
  • 项目类别:
"Determinants of T Cell Immunity to Tuberculosis Vaccines"
“T细胞对结核疫苗免疫的决定因素”
  • 批准号:
    8871648
  • 财政年份:
    2015
  • 资助金额:
    $ 33.5万
  • 项目类别:
Flow Cytometry Core
流式细胞术核心
  • 批准号:
    8871652
  • 财政年份:
    2015
  • 资助金额:
    $ 33.5万
  • 项目类别:
Construction of safe and effective live tuberculosis vaccines
安全有效的结核活疫苗的构建
  • 批准号:
    8230473
  • 财政年份:
    2011
  • 资助金额:
    $ 33.5万
  • 项目类别:
Defining the Correlates of Bactericidal Immunity in Tuberculosis
定义结核病杀菌免疫的相关性
  • 批准号:
    8031491
  • 财政年份:
    2011
  • 资助金额:
    $ 33.5万
  • 项目类别:
Construction of safe and effective live tuberculosis vaccines
安全有效的结核活疫苗的构建
  • 批准号:
    8626351
  • 财政年份:
    2011
  • 资助金额:
    $ 33.5万
  • 项目类别:
"Determinants of T Cell Immunity to Tuberculosis Vaccines"
“T细胞对结核疫苗免疫的决定因素”
  • 批准号:
    8049854
  • 财政年份:
    2011
  • 资助金额:
    $ 33.5万
  • 项目类别:
Construction of safe and effective live tuberculosis vaccines
安全有效的结核活疫苗的构建
  • 批准号:
    8083413
  • 财政年份:
    2011
  • 资助金额:
    $ 33.5万
  • 项目类别:

相似海外基金

Development of Enhanced Anti-inflammatory Blood Mononuclear Cell Therapy for ARDS and Elucidation of the Molecular Mechanism
ARDS增强抗炎血液单核细胞治疗的进展及分子机制的阐明
  • 批准号:
    23K07659
  • 财政年份:
    2023
  • 资助金额:
    $ 33.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Exploring therapeutic effects of anti-inflammatory and resolving factors in osteoporosis model mice
探讨抗炎和缓解因子对骨质疏松模型小鼠的治疗作用
  • 批准号:
    23K15705
  • 财政年份:
    2023
  • 资助金额:
    $ 33.5万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Investigation of the relation between age-related estradiol fluctuation and pro-/anti-inflammatory effects in transplant immune response.
研究年龄相关雌二醇波动与移植免疫反应中促/抗炎作用之间的关系。
  • 批准号:
    23K19490
  • 财政年份:
    2023
  • 资助金额:
    $ 33.5万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Non-coating anti-microbial, anti-host protein deposition, anti-inflammatory urinary catheter
无涂层抗菌、抗宿主蛋白沉积、抗炎导尿管
  • 批准号:
    10697567
  • 财政年份:
    2023
  • 资助金额:
    $ 33.5万
  • 项目类别:
Identification and optimization of verapamil as a novel neuroprotective and anti-inflammatory agent for reducing long-term neurological morbidities following organophosphate-induced status epilepticus
维拉帕米作为新型神经保护和抗炎剂的鉴定和优化,用于减少有机磷引起的癫痫持续状态后的长期神经系统发病率
  • 批准号:
    10727765
  • 财政年份:
    2023
  • 资助金额:
    $ 33.5万
  • 项目类别:
Anti-inflammatory Effects of Hydrogen Gas Produced by Gut Microflora in a Mouse Model of ARDS
肠道菌群产生的氢气对 ARDS 小鼠模型的抗炎作用
  • 批准号:
    23K08467
  • 财政年份:
    2023
  • 资助金额:
    $ 33.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Knockdown of AdipoR2 Compromises Adiponectin’s Anti-inflammatory Actions by Mainly Promoting a Pro-inflammatory Chemokine and Cytokine Secretory Profile in THP-1 Macrophages
AdipoR2 的敲低主要通过促进 THP-1 巨噬细胞中促炎趋化因子和细胞因子的分泌特征来损害脂联素的抗炎作用
  • 批准号:
    493138
  • 财政年份:
    2023
  • 资助金额:
    $ 33.5万
  • 项目类别:
Elucidation of anti-inflammatory mechanism of surface layer protein of lactic acid bacteria focusing on its interaction with lipopolysaccharide.
阐明乳酸菌表面层蛋白的抗炎机制,重点关注其与脂多糖的相互作用。
  • 批准号:
    23K13905
  • 财政年份:
    2023
  • 资助金额:
    $ 33.5万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
SBIR Phase I: Structure-guided design of anti-inflammatory modulators of protease-activated receptor 1 (PAR1)
SBIR I 期:蛋白酶激活受体 1 (PAR1) 抗炎调节剂的结构引导设计
  • 批准号:
    2223225
  • 财政年份:
    2023
  • 资助金额:
    $ 33.5万
  • 项目类别:
    Standard Grant
Targeting anti-viral and anti-inflammatory responses during ocular HSV-1 infection to prevent vision impairment.
针对眼部 HSV-1 感染期间的抗病毒和抗炎反应,以预防视力障碍。
  • 批准号:
    10651054
  • 财政年份:
    2023
  • 资助金额:
    $ 33.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了